Navigation Links
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
Date:4/23/2009

48-week investigational regimen yielded nearly double SVR rate compared to standard of care

Update on next-generation HCV protease inhibitor SCH 900518 presented at EASL annual meeting

COPENHAGEN, Denmark, April 23 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that final results of the HCV SPRINT-1 study showed boceprevir, its investigational oral hepatitis C protease inhibitor, in combination with peginterferon alfa-2b and ribavirin, significantly increased sustained virologic response (SVR)(1) rates with 28 and 48 weeks of therapy compared to current standard of care, peginterferon and ribavirin for 48 weeks (control group). The results from this Phase II study in 595 treatment-naive patients with chronic hepatitis C virus (HCV) genotype 1 were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting.(2) Genotype 1 is the most common and hardest to treat form of hepatitis C.

In Part I of the study, a 48-week boceprevir regimen achieved a 75 percent SVR rate (n=77/103) in patients who received 4 weeks of PEGINTRON(TM) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) (P/R) followed by the addition of boceprevir (800 mg TID) for 44 weeks (boceprevir P/R lead-in regimen). This represents a near doubling of the 38 percent SVR rate (n=39/104) for patients in the control group (p<0.0001). In a 28-week boceprevir P/R lead-in regimen 56 percent of patients (n=58/103) achieved SVR (p=0.005).(3)

Importantly, the likelihood (predictability) of attaining SVR was greater for patients who received the boceprevir P/R lead-in regimens compared to the no lead-in arms. Of patients in the boceprevir P/R lead-in arms who achieved a rapid virologic response (RVR), 94 percent in the 48-week regimen and 82 percent in the 28-week r
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
2. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
5. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
6. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
7. Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Final Results of Ideal Study Presented at Annual Meeting of the European Association for the Study of the Liver (EASL)
10. The Anatomy of Clinical Trials: Greys Season Finale Leaves Public in the Dark About the Myths and Realities
11. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... , October 17, 2014 ... Pharmaceuticals Inc. (NASDAQ: ARNA ), NPS Pharmaceuticals ... XOMA ), Momenta Pharmaceuticals Inc. (NASDAQ: ... CPRX). Free research on these five companies can be ... markets on Thursday, October 16, 2014, ended on a ...
(Date:10/17/2014)... KIRKLAND, Wash. , Oct. 17, 2014  Talyst, ... at the 2014 LeadingAge Annual Meeting in ... its InSite System, the market leading solution for onsite, ... enables long term care facilities to safely and securely ... on time to first dose, helps ensure that the ...
(Date:10/17/2014)... 17, 2014   InnFocus, Inc ., reported on results ... States for up to 3 years with the ... in Chicago . The Summit ... annual meeting of the American Academy of Ophthalmology . ... 150 glaucoma patients in 6 countries by early 2015. ...
Breaking Medicine Technology:Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 2Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 3Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 4Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners 5Talyst Exhibits at LeadingAge Annual Meeting 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2
... Aug. 4 /PRNewswire-Asia-FirstCall/ -- China Nepstar Chain,Drugstore Ltd. ... Company"), the largest retail,drugstore chain in China based ... State Administration of Foreign Exchange imposed on,the company a one-time ... US$3.8 million ) for the conversion of approximately US$349 ...
... CITY , Aug. 3 Graymark Healthcare, Inc. (Nasdaq: ... CDT on Tuesday, August 10, 2010 , to discuss the company,s ... and provide an update on the company. , ... The conference call will be webcast on the investor ...
Cached Medicine Technology:China Nepstar Chain Drugstore Reports One-time Non-recurring Penalty Payment 2China Nepstar Chain Drugstore Reports One-time Non-recurring Penalty Payment 3China Nepstar Chain Drugstore Reports One-time Non-recurring Penalty Payment 4Graymark Healthcare, Inc. to Host Conference Call to Discuss Q2 Financial Results 2
(Date:10/20/2014)... 20, 2014 Principle Business Enterprises, a ... in manufacturing top-of-the-line absorbent products. The company has ... most popular brand, Tranquility® Premium Protection absorbent products. ... website, gave its packaging a new look, and is ... message to the public. , The new website, developed ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked in the ... Every Body Walk! campaign by Kaiser Permanente. Every ... to be more active outside of the workplace. This ... end of September, was a friendly competition between organizations across ... companies gave their staff pedometers and each day, for the ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... Spring, Maryland, USA (PRWEB) October 20, 2014 ... or to track interventions? Here comes a wonderful app ... mobile app development company helped its client ... Intervention more efficiently. The app is designed for iOS ... and iPod touch. This app is optimized for iPhone ...
(Date:10/19/2014)... NATIONS, New York (PRWEB) October 19, 2014 ... United Nations Population Fund, welcomes news of a ceasefire ... of the more than 200 girls who were kidnapped ... "These girls have languished in captivity long enough, and ... families, schools and communities," stated Dr. Osotimehin. , "We ...
Breaking Medicine News(10 mins):Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... Kan., Jan. 28 Fort Dodge Animal Health,a ... the American Association of Equine,Practitioners (AAEP) recently announced ... raise awareness regarding the health of horses.,Americashealthyhorse.com provides ... The America,s Healthy Horse Web site will aide ...
... -- The Cystic Fibrosis Foundation reported today that key ... including lung function and nutritional status -- are rising ... fact, the outlook for people with CF continues to ... accelerating due to quality improvement programs spearheaded by the ...
... To support,Pennsylvanians who made a New Year,s resolution ... announced that Governor Edward G.,Rendell has proclaimed Jan. 28 ... "Determined to Quit Week is all about motivating Pennsylvanians ... Secretary of,Health Dr. Calvin B. Johnson. "For anyone who ...
... to Expand Profile with Area Representatives, TAMPA, ... leading study program, announces a new program to ... Area,Representatives will travel to massage schools nationwide to ... so comprehensive that,Massage Prep guarantees passage of the ...
... ... Presenting at the UBS Global Healthcare Services Conference on Tuesday, ... February 12, 2008, CINCINNATI, Jan. ... the,LasikPlus brand, announced today upcoming investment community events., Fourth Quarter & Full-Year 2007 ...
... Russian women who smoke has more than doubled since the ... In 1992, seven per cent of women smoked, compared to ... the number of men who smoke has risen from 57 ... the study, published in the journal Tobacco Control, blame the ...
Cached Medicine News:Health News:Fort Dodge Animal Health and the American Association of Equine Practitioners Launch Educational Web Site 2Health News:Cystic Fibrosis Foundation reports upward trend for key health outcomes 2Health News:Massage Prep(TM) Announces Outreach Program 2Health News:LCA-Vision Announces Upcoming Investment Community Events 2Health News:Number of Russian women smokers has doubled since Soviet collapse 2
Leica M500 MS3 robotic stand for neuro, spine surgery and ENT. Motorized XY-movement for precise positioning of the optical axis in eight directions, inclination and tilt....
Advanced operating microscope with high-resolution apochromatic optics. Senso-servo drive to keep the microscope in perfect balance even if parts are moved or mounted elsewhere....
... provides surgeons with brighter, crisper, magnified views ... for many minimally invasive spine procedures. It ... point of contact. The first graphical touchscreen ... allows intuitive user guidance similar to that ...
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
Medicine Products: